Presented by: Momen M. Wahidi, MD, FCCP and W. Dean Wallace, MD

CHEST NSCLC 2016

Biomarker-driven targeted therapy of patients with NSCLC requires accurate diagnosis and staging. The pulmonary care team must acquire adequate biopsy tissue to enable histology, immunofluorescence and molecular biomarker testing. Presented in Los Angeles, California - October 2016.

Download SLIDES [pptx ยป 11MB]